Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 7:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 1,399 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: SoC Clear all
Active, not recruiting Phase 2 Interventional

Treatment of ARDS With Instilled T3

NCT04115514
View directory record Official record
Conditions
ARDS, Human, Lung, Wet, Thyroid, Pulmonary Edema, Lung Inflammation
Interventions
Liothyronine Sodium (T3+0.9% sodium chloride) modified formulation specifically for airway instillation., Non-intervention
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Edina, Minnesota • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 22, 2026, 7:12 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Collaborative Care PrTNER Study

NCT06585631
View directory record Official record
Conditions
HIV, Substance Use Disorders, Substance Use, AIDS
Interventions
CC PrTNER
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
15 Years to 29 Years · Male only
Enrollment
275 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 22, 2026, 7:12 PM EDT
Completed Not applicable Interventional

Restricted or Liberal Antibiotics After Appendectomy - Denver Health

NCT05002829
View directory record Official record
Conditions
Appendicitis
Interventions
Restricted Duration of SOC Antibiotic Use, Liberal Duration of SOC Antibiotic Use
Other
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years and older
Enrollment
657 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 22, 2026, 7:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy

NCT04532372
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
Best Practice, Leflunomide, Placebo Administration
Other · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 22, 2026, 7:12 PM EDT
Not listed Not applicable Interventional

Assessment of the Effects on the Skin Microbiome of Amending an Over-the-counter Eczema Product With Activated Oil (AO)

NCT05413395
View directory record Official record
Conditions
Eczema
Interventions
topical colloidal oatmeal formulation with a modified plant oil, topical colloidal oatmeal formulation
Other
Lead sponsor
GlycosBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Oct 22, 2026, 7:12 PM EDT
Completed Not applicable Interventional Results available

The Influence of Time-Restricted Eating in Patients With Metabolic Syndrome

NCT04057339
View directory record Official record
Conditions
Metabolic Syndrome, Pre-Diabetes
Interventions
Time Restricted Eating + Standard of Care, Standard of Care
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 75 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 22, 2026, 7:12 PM EDT
Completed Phase 1 Interventional

Phase 1a Study to Evaluate Immunogenicity of ASV®

NCT03673020
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
ASV® AGEN2017 + QS-21 Stimulon® adjuvant
Biological
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Oct 22, 2026, 7:12 PM EDT
Completed Phase 3 Interventional

Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D

NCT02492620
View directory record Official record
Conditions
Chronic Kidney Disease, Hyperphosphatemia, Iron Deficiency Anemia, Renal Insufficiency
Interventions
Ferric Citrate
Drug
Lead sponsor
Denver Nephrologists, P.C.
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 22, 2026, 7:12 PM EDT
Completed Phase 3 Interventional Results available

Extension Study of Cinacalcet for Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Patients With Chronic Kidney Disease on Dialysis

NCT02341417
View directory record Official record
Conditions
Secondary Hyperparathyroidism, Chronic Kidney Disease
Interventions
Cinacalcet
Drug
Lead sponsor
Amgen
Industry
Eligibility
Up to 18 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
18
States / cities
Los Angeles, California • Tucker, Georgia • Baltimore, Maryland + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Oct 22, 2026, 7:12 PM EDT
Terminated Phase 1 Interventional Results available

Cefiderocol Concentrations in the Lungs of Hospitalized Patients With Bacterial Pneumonia

NCT03862040
View directory record Official record
Conditions
Bacterial Pneumonia
Interventions
Cefiderocol, Standard of Care Antibiotic
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
7
States / cities
Aurora, Colorado • Hartford, Connecticut • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Oct 22, 2026, 7:12 PM EDT
Recruiting Phase 2 Interventional

Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers

NCT05846789
View directory record Official record
Conditions
Metastatic Breast Cancer, Triple Negative Breast Cancer, Estrogen-receptor-low Breast Cancer, ER Positive, HER2 Negative Breast Cancer
Interventions
SOC Chemotherapy, Tocilizumab/Tocilizumab Biosimilar
Drug
Lead sponsor
Kathy Miller
Other
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Atlanta, Georgia • Carmel, Indiana • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 22, 2026, 7:12 PM EDT
Recruiting Phase 4 Interventional

A Multicenter, Prospective, Clinical Trial Evaluating a Single Layer Amniotic Membrane and Standard of Care Versus Matched Controls in the Management of Nonhealing Pressure Ulcers

NCT07126886
View directory record Official record
Conditions
Pressure Ulcer, Ulcer, Pressure, Pressure Wound, Pressure Area
Interventions
Standard of Care, XPURT + SOC
Other
Lead sponsor
Applied Biologics, LLC
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Monroeville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 22, 2026, 7:12 PM EDT
Terminated Not applicable Interventional

A Study to Investigate Two Atteris Antimicrobial Products on Chronic Wound Healing.

NCT03198169
View directory record Official record
Conditions
Chronic Wounds
Interventions
Atteris Antimicrobial Skin and Wound Cleanser, Atteris Antimicrobial Barrier Film Dressing
Device
Lead sponsor
Atteris Healthcare, LLC
Industry
Eligibility
18 Years to 89 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 22, 2026, 7:12 PM EDT
Withdrawn Phase 2 Interventional

Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Trauma Patients

NCT04531579
View directory record Official record
Conditions
Acute Kidney Injury, Ischemia Reperfusion Injury
Interventions
Valproic Acid Solution, Isotonic saline solution
Drug
Lead sponsor
Westat
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 22, 2026, 7:12 PM EDT
Enrolling by invitation Phase 4 Interventional

Intra-Articular Catheter Total Knee Arthroplasty

NCT06580899
View directory record Official record
Conditions
Continuous Local Infiltration Analgesia, Intra-articular Catheter, Total Knee Arthroplasty
Interventions
Intra-articular catheter, Routine Standard of Care Treatment
Device · Other
Lead sponsor
OrthoCarolina Research Institute, Inc.
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 22, 2026, 7:12 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis

NCT05371964
View directory record Official record
Conditions
Myelofibrosis
Interventions
Imetelstat sodium, Ruxolitinib
Drug
Lead sponsor
Geron Corporation
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
6
States / cities
Duarte, California • Irvine, California • Coral Gables, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 22, 2026, 7:12 PM EDT
Terminated Phase 2 Interventional Results available

Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)

NCT03345407
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Placebo ELLIPTA, Nemiralisib ELLIPTA 50 µg, Nemiralisib ELLIPTA 100 µg, Nemiralisib ELLIPTA 250 µg, Nemiralisib ELLIPTA 500 µg, Nemiralisib ELLIPTA 750 µg, Albuterol (Salbutamol) MDI or nebules, Standard of care therapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
943 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
21
States / cities
Mobile, Alabama • Colorado Springs, Colorado • Daytona Beach, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Oct 22, 2026, 7:12 PM EDT
Recruiting Phase 1 Interventional

Momelotinib During and After HCT in Myelofibrosis

NCT07104799
View directory record Official record
Conditions
Myelofibrosis, Hematopoietic Cell Transplantation (HCT)
Interventions
Momelotinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 22, 2026, 7:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.

NCT03345485
View directory record Official record
Conditions
Small Cell Lung Cancer, Soft Tissue Sarcoma, Triple-negative Breast Cancer, Ovarian Cancer, Endometrial Cancer
Interventions
Tinostamustine 60mg/m2 over 30min, Tinostamustine 80mg/m2 over 30min, Tinostamustine 100mg/m2 over 30min, Tinostamustine 60mg/m2 over 60min, Tinostamustine 80mg/m2 over 60min, Tinostamustine 100mg/m2 over 60min, Tinostamustine 80mg/m2 over 80min
Drug
Lead sponsor
Mundipharma Research Limited
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
5
States / cities
Los Angeles, California • Palo Alto, California • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Oct 22, 2026, 7:12 PM EDT
Completed Phase 2 Interventional

PMT for MDRO Decolonization

NCT05632315
View directory record Official record
Conditions
Multidrug Resistant Bacterial Infection, Enterobacteriaceae Infections, Pseudomonas Aeruginosa, VRE Infection, Methicillin-resistant Staphylococcus Aureus
Interventions
PMT
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Atlanta, Georgia • St Louis, Missouri • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 22, 2026, 7:12 PM EDT
Recruiting Phase 1Phase 2 Interventional

AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

NCT06137144
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL), PTCL-NOS, ALCL, AITL
Interventions
AZD3470, Pembrolizumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
7
States / cities
Duarte, California • Miami, Florida • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 22, 2026, 7:12 PM EDT
Recruiting Not applicable Interventional

A Study Evaluating the Impact of P-tau217 Blood Biomarker Testing on Early Evaluation and Management of Patients Presenting With Cognitive Complaint

NCT07140744
View directory record Official record
Conditions
Subjective Cognitive Impairment
Interventions
P-tau217, Standard of Care
Diagnostic Test · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years and older
Enrollment
7,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 22, 2026, 7:12 PM EDT
Active, not recruiting Phase 3 Interventional

Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin

NCT04960709
View directory record Official record
Conditions
Muscle Invasive Bladder Cancer
Interventions
Durvalumab, Tremelimumab, Enfortumab Vedotin, Radical Cystectomy
Drug · Procedure
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
712 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
31
States / cities
Orange, California • Santa Monica, California • New Haven, Connecticut + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 22, 2026, 7:12 PM EDT
Recruiting Phase 1 Interventional

A Trial Utilizing 18F-FS PG PET to Guide Therapy in Hepatocellular Carcinoma

NCT07116486
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Radiopharmaceutical 18F-FSPG
Diagnostic Test
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 22, 2026, 7:12 PM EDT